Preventing respiratory syncytial virus infections

Area of Science:

• Pediatrics
• Infectious Diseases
• Immunology

Background:

• Respiratory syncytial virus (RSV) is the primary cause of lower respiratory tract infections in infants and young children.
• Palivizumab, a monoclonal antibody, is approved to prevent RSV-related hospitalizations in high-risk children.
• Current treatment guidelines require updates to reflect recent changes in clinical practice and recommendations.

Purpose of the Study:

• To review the efficacy and cost-effectiveness of palivizumab for preventing RSV hospitalizations.
• To provide updated recommendations for palivizumab use in high-risk pediatric populations within the Canadian context.
• To integrate recent guideline changes from the American Academy of Pediatrics into Canadian clinical practice.

Main Methods:

• Systematic review of published literature on palivizumab efficacy, safety, and cost-effectiveness.
• Analysis of recent guideline updates from major pediatric organizations.
• Development of evidence-based recommendations for palivizumab administration.

Main Results:

• Palivizumab demonstrates efficacy in reducing RSV hospitalization rates among specific high-risk pediatric groups.
• The high cost of palivizumab remains a significant consideration for widespread use.
• Updated guidelines suggest a more nuanced approach to patient selection for palivizumab prophylaxis.

Conclusions:

• Palivizumab remains a valuable tool for preventing severe RSV disease in carefully selected high-risk infants.
• Recommendations emphasize a thorough assessment of individual risk factors and cost-benefit analysis.
• Ongoing evaluation of palivizumab's role in RSV prevention is warranted, considering evolving clinical evidence and healthcare resource allocation.